Press coverage about Spring Bank Pharmaceuticals (NASDAQ:SBPH) has trended somewhat positive recently, Accern Sentiment Analysis reports. The research firm ranks the sentiment of news coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Spring Bank Pharmaceuticals earned a news sentiment score of 0.16 on Accern’s scale. Accern also assigned news headlines about the company an impact score of 45.4138017828008 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.
Spring Bank Pharmaceuticals (NASDAQ SBPH) traded up $0.37 on Tuesday, hitting $12.50. The stock had a trading volume of 29,500 shares, compared to its average volume of 35,693. Spring Bank Pharmaceuticals has a one year low of $6.31 and a one year high of $18.93.
SBPH has been the subject of several research reports. B. Riley initiated coverage on Spring Bank Pharmaceuticals in a research note on Monday, November 6th. They set a “buy” rating and a $30.00 price objective for the company. ValuEngine lowered Spring Bank Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Thursday, August 24th. Chardan Capital reissued a “buy” rating on shares of Spring Bank Pharmaceuticals in a research note on Monday, November 6th. Finally, Cantor Fitzgerald set a $29.00 price objective on Spring Bank Pharmaceuticals and gave the stock a “buy” rating in a research note on Thursday, November 16th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and four have issued a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus price target of $27.25.
About Spring Bank Pharmaceuticals
Spring Bank Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of a class of therapeutics using its small molecule nucleic acid hybrid (SMNH) chemistry platform. The Company is developing its SMNH product, SB 9200, for the treatment of viral diseases.
What are top analysts saying about Spring Bank Pharmaceuticals? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Spring Bank Pharmaceuticals and related companies.